tomm-7 Antibody

Target Overview

TOMM7 (Translocase of Outer Mitochondrial Membrane 7) is a 6 kDa subunit of the TOM complex essential for mitochondrial protein import . Antibodies against TOMM7 enable detection and functional studies of this key regulatory protein involved in:

• Assembly/stability of the TOM complex

• PARK2/PINK1-mediated mitophagy

• Mitochondrial respiration-glycolysis balance

Cerebrovascular Pathogenesis

A recurrent homozygous TOMM7 p.P29L variant was identified in 9 patients showing:

• Postnatal growth failure (100% incidence)

• Moyamoya disease (55% incidence)

• Mitochondrial enlargement (+42% volume)

• Glycolytic shift:

  • ATP from glycolysis ↑ 2.8-fold

  • Oxygen consumption rate ↓ 18%

CRISPR-edited iPSC endothelial cells revealed:

Angiogenic Regulation

TOMM7 deficiency in endothelial cells causes:

• Impaired capillary branching (↓37% density)

• Mitochondrial ROS ↑ 2.5-fold

• Complex I activity ↓ 41%

Zebrafish models demonstrated:

• 84% rescue of vascular defects with endothelial-specific TOMM7 expression

• Rac1-dependent oxidative stress mediates angiogenic failure

Experimental Applications

Validated protocols using TOMM7 antibodies:

Western Blotting

• Lysate: 20 µg mitochondrial fraction

• Primary antibody: 1:500 dilution

• Detection: Chemiluminescence with 60s exposure

Immunohistochemistry

• Antigen retrieval: TE buffer pH 9.0

• Blocking: 5% BSA/1h

• Signal development: DAB 5min

Emerging Clinical Connections

Recent studies propose diagnostic/therapeutic implications:

• Atrophic macular scarring as early biomarker (100% specificity in cohort)

• Hexokinase 2 upregulation (+3.2-fold) suggests glycolytic inhibitors as potential therapeutics

• Moyamoya disease correlation demands vascular monitoring in TOMM7 mutation carriers